| SEC For | m 4 | | | | | | | | | | | | | | | | | |
|--|--|-----|---|---------------------|--|--|--|----------------|--|---------------------|---|---------------------|--|---|---------------------------------|---|--|--|
| FORM 4 | | | UNITED STATES SECURITIES AND EXCHANGE COMMI Washington, D.C. 20549 | | | | | | | | | | | | OMB APPROVAL | | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | CMB Number: 32 Estimated average burden hours per response: | | | | 3235-0287 1 0.5 |
| 1. Name and Address of Reporting Person [*] Jiao Jin-an | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>HCW Biologics Inc.</u> [HCWB] | | | | | | | | | elationship o eck all applio Directo Officer | cable) | g Perso | on(s) to Iss 10% Ov Other (s | /ner |
| (Last) (First) (Middle) C/O HCW BIOLOGICS INC 2929 N. COMMERCE PARKWAY | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/31/2022 | | | | | | | | | below) | below) VP of Develop | | | |
| (Street) MIRAMAR FL 33025 | | | | | 4. If Ame | Line) X Form file | | | | | | | oint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | | | |
| | | Tab | le I - Nor | -Deriv | ative Se | ecurities Ac | qui | ired, | Disp | osed o | f, o | r Bene | eficiall | y Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Trans: Date (Month/E | | | | action Day/Year) | Execution Date, | | Code (Inst | | 4. Securities Acquired (<i>i</i> Disposed Of (D) (Instr. 3 5) | | (A) or 3, 4 and | Benefici Owned F | es ally Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | Code | v | Amount | | (A) or (D) | Price | Reported Transact (Instr. 3 | tion(s) | | | (Instr. 4) |
| Common Stock | | | | 05/31 | /2022 | | | М | | 12,856 | | A | \$0.14 | 4 43 | 43,427 | | D | |
| Common Stock 05/31/ | | | | /2022 | 2022 | | М | | 1,714 | | Α | \$0.2 | L 45 | ,141 | | D | | |
| | | 1 | Fable II - I (| Derivat (e.g., p | tive Sec uts, call | urities Acq ls, warrants | uire 5, oj | ed, D ption | ispo s, co | sed of, onvertil | or ble : | Benef securi | icially ties) | Owned | | | | |
| 1. Title of Derivative Security (Instr. 3) | rivative Conversion Date Execution curity or Exercise (Month/Day/Year) if any | | 3A. Deemed Execution I if any (Month/Day | Date, T | ransaction ode (Instr. | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable Expiration Date (Month/Day/Year) | | | | 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4) | | s ecurity | 8. Price of Derivative Security (Instr. 5) | erivative ecurity Securities | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |

Explanation of Responses:

\$0.14

\$0.21

1. These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest on May 30, 2020; and 35% of the total shares subject to the stock option grant will vest option gran May 30, 2023.

Date Exercisable

(1)

(2)

Expiration Date

05/29/2029

12/22/2030

Title

Stock

Common

Stock

2. Ov of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024.

Remarks:

Stock Option

(Right to Buy)

Stock Option

Buy)

(Right to

/s/ Jin-an Jiao ** Signature of Reporting Person

Amount or Number

Shares

12,856

1,714

\$0.00

\$0.00

of

06/02/2022 Date

18,001

6.857

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/31/2022

05/31/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

v

(A) (D)

12,856

1.714

Code

Μ

Μ

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.